These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9826216)

  • 1. Treatment with growth hormone suppresses cortisol production in man.
    Vierhapper H; Nowotny P; Waldhäusl W
    Metabolism; 1998 Nov; 47(11):1376-8. PubMed ID: 9826216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unchanged testosterone production rates in growth hormone-treated healthy men.
    Vierhapper H; Nowotny P; Waldhäusl W
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3735-6. PubMed ID: 9768692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-specific differences in cortisol production rates in humans.
    Vierhapper H; Nowotny P; Waldhäusl W
    Metabolism; 1998 Aug; 47(8):974-6. PubMed ID: 9711994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism.
    Garrel DR; Moussali R; De Oliveira A; Lesiège D; Larivière F
    J Clin Endocrinol Metab; 1995 Feb; 80(2):379-85. PubMed ID: 7888013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
    Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
    J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cortisol response to ACTH in pigs, heritability and influence of corticosteroid-binding globulin.
    Larzul C; Terenina E; Foury A; Billon Y; Louveau I; Merlot E; Mormede P
    Animal; 2015 Dec; 9(12):1929-34. PubMed ID: 26302113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-hour infusion of hydrocortisone does not suppress the nocturnal increase of circulating acyl- or desacyl-ghrelin concentrations in healthy young adults.
    Nass R; Liu J; Patrie J; Pezzoli SS; Farhy LS; Gaylinn BD; Thorner MO
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1696-700. PubMed ID: 24963646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4039-46. PubMed ID: 11095430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.
    Jacks T; Hickey G; Judith F; Taylor J; Chen H; Krupa D; Feeney W; Schoen W; Ok D; Fisher M
    J Endocrinol; 1994 Nov; 143(2):399-406. PubMed ID: 7830002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
    Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
    J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
    Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
    Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of administration of human growth hormone on the plasma growth hormone, cortisol, glucose, and free fatty acid response to insulin: evidence for growth hormone autoregulation in man.
    Abrams RL; Grumbach MM; Kaplan SL
    J Clin Invest; 1971 Apr; 50(4):940-50. PubMed ID: 4926262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Di Vito L; Broglio F; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study.
    Juul A; Andersson AM; Pedersen SA; Jørgensen JO; Christiansen JS; Groome NP; Skakkebaek NE
    Horm Res; 1998; 49(6):269-78. PubMed ID: 9623518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid modulation of the effects of repeated stress on ACTH, cortisol, prolactin, and growth hormone in pigs.
    Rushen J; Schwarze N; Ladewig J; Foxcroft G
    Physiol Behav; 1993 May; 53(5):923-8. PubMed ID: 8390062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
    Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
    Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
    Rigamonti AE; Bonomo SM; Cella SG; Müller EE
    J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.